SCHEDULE: RTW Investments Discloses 5.7% Stake in Beta Bionics

RTW Investments, LP and Roderick Wong, M.D. have reported beneficial ownership of 5.7% of Beta Bionics, Inc.'s common stock.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively reported beneficial ownership of 2,500,000 shares of Beta Bionics, Inc. common stock.
• This represents 5.7% of the company's outstanding common stock.
• The percentage is calculated based on 44,024,631 shares outstanding as of October 24, 2025, as reported in Beta Bionics' Form 10-Q.
• The shares are held by RTW Funds, for which RTW Investments acts as an investment adviser and Dr. Wong is the Managing Partner and Chief Investment Officer.
• The Reporting Persons share both voting and dispositive power over all 2,500,000 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by a reputable healthcare investment firm like RTW Investments can be interpreted as a vote of confidence in Beta Bionics' long-term potential and strategic direction.

Positives

• Significant institutional investment by RTW Investments, LP, a specialized healthcare investment firm, signals confidence in Beta Bionics.
• The acquisition of shares was in the ordinary course of business, indicating a standard investment strategy rather than an activist intent.

Negatives

• NA

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, which could limit the potential for activist engagement to drive immediate strategic changes.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a 5.7% stake by RTW Investments, a prominent healthcare-focused investment firm, suggests a strategic interest in Beta Bionics, a company operating in the medical device or biotechnology sector. Such an investment by a specialized fund often indicates a belief in the long-term potential of the company's technology or market position within the healthcare industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by RTW Investments may instill greater confidence among existing shareholders and potentially attract new investors, given RTW's expertise in the healthcare sector.
• Company Management: The presence of a significant institutional investor could lead to increased scrutiny or engagement, even if the stated intent is passive.

Key Dates

Recommendation

The disclosure of a significant institutional stake by RTW Investments is a positive signal, suggesting confidence in Beta Bionics. However, without additional financial or operational updates from the company, a "hold" recommendation is prudent, acknowledging the positive investor interest while awaiting further fundamental catalysts.

Keywords

Beta Bionics, RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Healthcare Investment